Skip to main content
. 2024 Feb 23;102(6):e208051. doi: 10.1212/WNL.0000000000208051

Figure 2. Treatment Exposure in the Study Population.

Figure 2

(A) Late-onset multiple sclerosis (LOMS); (B) Adult-onset multiple sclerosis. PPMS = primary progressive multiple sclerosis; RRMS = relapsing-remitting multiple sclerosis. Modest (efficacy) DMT: interferon beta-1a, interferon beta-1b, pegylated interferon beta-1a, glatiramer acetate, dimethyl fumarate, and teriflunomide. High (efficacy) DMT: rituximab, ocrelizumab, natalizumab, alemtuzumab, fingolimod, cladribine, daclizumab, and autologous hematopoietic stem cell transplantation.